New Breakthroughs in IgA Nephropathy Treatment

This article is from our Spring 2026 issue. Read the full issue here.

IgA nephropathy (IgAN), sometimes called Berger’s disease, is a kidney condition caused by a buildup of an immune protein called immunoglobulin A (IgA) in the kidneys.

Over time, this buildup can lead to inflammation that affects how well the kidneys filter waste from the blood. For some people, the disease can progress to chronic kidney disease or kidney failure—but research is bringing new understanding and new options.

For many years, treatment for IgA nephropathy focused mainly on managing symptoms, such as controlling blood pressure and reducing protein in the urine.

While these steps remain important, recent advances in research have opened the door to therapies that go beyond symptom management and begin to address the underlying causes of the disease.

A Clearer Picture of IgA Nephropathy

Researchers now understand more about how IgA nephropathy begins. In people with the condition, the immune system produces a form of IgA that the body recognizes as abnormal. This triggers immune complexes that travel through the bloodstream and settle in the kidneys, where they cause inflammation and gradual damage.

This clearer picture of the disease has been a turning point—allowing scientists to design treatments that target specific steps in the disease process.

New and Emerging Treatment Options

One major breakthrough involves targeted steroid therapies that focus on the gut, where abnormal IgA is believed to originate. By acting closer to the source of the problem, these treatments aim to reduce harmful IgA production while limiting the side effects often associated with traditional steroids.

Researchers have also developed medications that block parts of the complement system, an immune pathway involved in kidney inflammation. In clinical studies, these treatments have shown the ability to reduce kidney inflammation and slow disease progression.

Another promising approach includes medications that help reduce protein leakage in the urine and protect the kidneys from long-term scarring. Lowering protein in the urine is an important marker of disease control and is linked to better kidney outcomes.

What This Means for Patients and Families

These advances represent a meaningful shift for people living with IgA nephropathy. For the first time, treatments are becoming available that are designed specifically for this disease—rather than relying only on general kidney-protective care.

While IgA nephropathy does not yet have a cure, newer therapies may help preserve kidney function and slow progression for many patients. Ongoing research continues to explore additional treatment options, combination approaches, and ways to personalize care based on individual risk factors.

For patients and families, this progress brings something important: more options, more knowledge, and more hope for the future.